Market Briefs

Headlines

SANp
Dupixent approval in Japan for bullous pemphigoid with Sanofi branding and clinical trial reference

Japan clears Dupixent for bullous pemphigoid

Sanofi's Dupixent wins Japanese nod for rare blistering disease after strong Phase 2/3 results; Q1 memo out.

March 24, 2026

4 min read

Goldman’s Top Healthcare Picks Gain Fresh Catalysts

Clinical wins and analyst upgrades spark renewed momentum across big pharma and biotech stocks.

Mar 15, 2026

4 min read

Azoria ETFs shut, Novartis India stake sold, tariff shock

Azoria ETFs liquidated amid legal woes; Novartis India stake sale and US tariff ruling spark market moves.

Feb 20, 2026

6 min read